Xcout IntelSavara, Inc.
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Subscribe to see Savara, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Savara, Inc. at a glance
Savara, Inc. is a biotechnology company headquartered in Langhorne, United States. It is publicly listed (SVRA) with a market capitalisation of $985.7M. Xcout tracks 21 named people at Savara, Inc., including Matthew Pauls (Chairman & Chief Executive Officer).
Savara, Inc. leadership
- Matthew PaulsChairman & Chief Executive Officer
- Matt PaulsChair of the Board of Directors, Chief Executive Officer
- Robert LutzCOO & CFO
- Yasmine WasfiChief Medical Officer
- Anne EricksonChief Business & Corporate Affairs Officer
- Braden ParkerChief Commercial Officer
15 more named people on record for Savara, Inc., with roles, board committees and tenure — see the full roster →
Savara, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $1.4M | — |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Savara, Inc. competitors
A few of Savara, Inc.'s closest competitors — see the full list of competitors and alternatives →
Sunterra Bio is a biopharmaceutical company focused on developing inhaled small-molecule therapies for rare pulmonary diseases. Headquartered in Carlsbad, California, the company advances targeted treatments for respiratory conditions.
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
Altesa BioSciences is a clinical-stage pharmaceutical company headquartered in College Park, Georgia. The company is dedicated to improving the lives of individuals suffering from chronic lung diseases, including conditions such as COPD and asthma.
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
Ollin Biosciences is a clinical-stage biopharmaceutical holding company established in 2023 and headquartered in Austin, Texas, dedicated to developing therapeutics.
Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company that engages in the development of products to address pulmonary hypertension related to interstitial lung disease.
Get Savara, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Savara, Inc. in Xcout Intel
- 21 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access